Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
Ferring Pharmaceuticals said on September 5 that it submitted a new drug application in Japan on August 27 for nadofaragene firadenovec, a non-replicating gene therapy for non-muscle invasive bladder cancer (NMIBC). The product, which carries the interferon alfa-2b gene, is…
To read the full story
Related Article
- Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
May 12, 2026
- Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
April 21, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
March 31, 2026
- Gene Therapies from Ferring, Ultragenyx in Line for Orphan Status, Moderna mRNA Drug Too
December 10, 2024
BUSINESS
- Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
- Regeneron Japan Files First Dual-AAV Therapy for Genetic Hearing Loss
July 30, 2026
- Shionogi’s Xocova Debuts in US for COVID-19 PEP
July 30, 2026
- Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
- Leqembi Global Sales Rise to 29.3 Billion Yen in April-June: Eisai
July 30, 2026
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…